Pneumothorax, nodule, effusion, seen early.
The chest concentrates vital emergencies and screening. The Milvue Suite detects pneumothorax, opacities, pleural effusions and pulmonary nodules (Europe coverage) - so nothing slips through the flow.
The extra eye on every chest.
Pneumothorax, opacities, pleural effusions, pulmonary nodules: chest detection flags and localizes abnormalities, urgent and silent alike.
- Pneumothorax and pleural effusion
- Opacities and pulmonary nodules
- +22% sensitivity in detection
- Critical cases prioritized
Three steps, zero friction.
No break in the chain, no workstation change: the solution slots into your existing flow.
Chest image
PA or lateral radiograph, no specific protocol.
Multi-pathology detection
Abnormalities localized with a confidence score.
Flag & report
Critical cases prioritized, results insert into the report.
A very simple tool to use, easy to interpret, with an instant automated result - on the chest as on the skeleton.
The facts, no noise.
CE-marked medical device, Class IIa, developed by Milvue. Native integration, protected data.
| Modalities | Chest radiography (PA / lat) |
|---|---|
| Pathologies | Pneumothorax, opacity, effusion, nodule |
| Population | Adult and pediatric · Europe coverage only |
| Output | Localized detection, returned on the image |
| Integration | Native RIS / PACS |
| Device | CE marked, class IIa (EU) · FDA: SmartChest (US) * |
Regulatory detail:
- The Milvue Suite (SmartUrgences module), developed by Milvue, is a Class IIa medical device according to EU MDR Regulation 2017/745 - Notified Body: BSI, CE 2797.
- In the United States, SmartChest is FDA cleared (Class II device). Not certified in Canada.